gabapentin has been researched along with Anxiety Disorders in 16 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Anxiety Disorders: Persistent and disabling ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We will include all randomised controlled trials (RCTs) reported as double-blind and comparing gabapentin or pregabalin with placebo or any other active pharmacological treatment (any preparation, dose, frequency, route of delivery or setting) in patients with bipolar disorder, anxiety or insomnia." | 8.95 | Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. ( Atkinson, LZ; Awad, A; Cipriani, A; Forrest, A; Geddes, JR; Harrison, PJ; Houghton, KT; Stockton, S, 2017) |
| "We evaluated effectiveness and predictors of response of gabapentin (GBP) as adjunctive treatment in a sample of 43 subjects with DSM-III-R bipolar disorder who were resistant to standard mood stabilizers." | 7.71 | Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? ( Akiskal, HS; Frare, F; Moretti, L; Perugi, G; Ruffolo, G; Toni, C; Torti, C, 2002) |
| "We will include all randomised controlled trials (RCTs) reported as double-blind and comparing gabapentin or pregabalin with placebo or any other active pharmacological treatment (any preparation, dose, frequency, route of delivery or setting) in patients with bipolar disorder, anxiety or insomnia." | 4.95 | Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. ( Atkinson, LZ; Awad, A; Cipriani, A; Forrest, A; Geddes, JR; Harrison, PJ; Houghton, KT; Stockton, S, 2017) |
| "We evaluated effectiveness and predictors of response of gabapentin (GBP) as adjunctive treatment in a sample of 43 subjects with DSM-III-R bipolar disorder who were resistant to standard mood stabilizers." | 3.71 | Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? ( Akiskal, HS; Frare, F; Moretti, L; Perugi, G; Ruffolo, G; Toni, C; Torti, C, 2002) |
| "Forty adult patients with partial epilepsy were studied in a prospective, non-randomized fashion with interviewer-rated and self-rated scales of mood and anxiety: the Cornell Dysthymia Rating Scale (CDRS), Beck Depression Inventory (BDI), and Hamilton Depression (Ham-D) and Anxiety (Ham-A) Scales." | 2.69 | A beneficial effect on mood in partial epilepsy patients treated with gabapentin. ( Carson, D; Goldstein, MA; Harden, CL; Kocsis, JH; Labar, DR; Lazar, LM; Nikolov, B; Pick, LH; Ravdin, LD, 1999) |
| "This review aims to analyze pharmacokinetic profile, plasma level variations so as the metabolism, interactions and possible relation to clinical effect of several drugs which are used primarily as anxiolytics." | 2.49 | Understanding the pharmacokinetics of anxiolytic drugs. ( Altamura, AC; Bareggi, S; Maffini, M; Mauri, MC; Moliterno, D; Paletta, S, 2013) |
| "Pediatric epilepsy is a common, chronic, and challenging physical illness for children and their families." | 2.46 | Psychiatric concerns in pediatric epilepsy. ( Bujoreanu, IS; DeMaso, DR; Ibeziako, P, 2010) |
| "Cases with EoE with a psychiatric diagnosis were more likely to be women, white, and 18 years or older and to have a longer symptom duration before diagnosis." | 1.56 | Psychiatric Comorbidities and Psychiatric Medication Use Are Highly Prevalent in Patients With Eosinophilic Esophagitis and Associate With Clinical Presentation. ( Corder, SR; Dellon, ES; Eluri, S; Kim, E; Reed, CC; Sanders, E; Tappata, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Mocanu, V | 1 |
| Wood, E | 1 |
| Reed, CC | 1 |
| Corder, SR | 1 |
| Kim, E | 1 |
| Sanders, E | 1 |
| Tappata, M | 1 |
| Eluri, S | 1 |
| Dellon, ES | 1 |
| Houghton, KT | 1 |
| Forrest, A | 1 |
| Awad, A | 1 |
| Atkinson, LZ | 1 |
| Stockton, S | 1 |
| Harrison, PJ | 1 |
| Geddes, JR | 1 |
| Cipriani, A | 1 |
| Greenblatt, HK | 1 |
| Greenblatt, DJ | 1 |
| Bujoreanu, IS | 1 |
| Ibeziako, P | 1 |
| DeMaso, DR | 1 |
| Steiger, A | 1 |
| Altamura, AC | 1 |
| Moliterno, D | 1 |
| Paletta, S | 1 |
| Maffini, M | 1 |
| Mauri, MC | 1 |
| Bareggi, S | 1 |
| Perugi, G | 1 |
| Toni, C | 1 |
| Frare, F | 1 |
| Ruffolo, G | 1 |
| Moretti, L | 1 |
| Torti, C | 1 |
| Akiskal, HS | 1 |
| Lydiard, RB | 1 |
| Blanco, C | 1 |
| Schneier, FR | 1 |
| Schmidt, A | 1 |
| Blanco-Jerez, CR | 1 |
| Marshall, RD | 1 |
| Sánchez-Lacay, A | 1 |
| Liebowitz, MR | 1 |
| Stahl, SM | 1 |
| Kaufman, KR | 1 |
| Hasnie, FS | 1 |
| Breuer, J | 1 |
| Parker, S | 1 |
| Wallace, V | 1 |
| Blackbeard, J | 1 |
| Lever, I | 1 |
| Kinchington, PR | 1 |
| Dickenson, AH | 1 |
| Pheby, T | 1 |
| Rice, AS | 1 |
| Chouinard, G | 1 |
| Beauclair, L | 1 |
| Bélanger, MC | 1 |
| Pollack, MH | 1 |
| Matthews, J | 1 |
| Scott, EL | 1 |
| Harden, CL | 1 |
| Lazar, LM | 1 |
| Pick, LH | 1 |
| Nikolov, B | 1 |
| Goldstein, MA | 1 |
| Carson, D | 1 |
| Ravdin, LD | 1 |
| Kocsis, JH | 1 |
| Labar, DR | 1 |
6 reviews available for gabapentin and Anxiety Disorders
| Article | Year |
|---|---|
Alcohol use disorder with comorbid anxiety disorder: a case report and focused literature review.
Topics: Alcoholism; Anxiety; Anxiety Disorders; Comorbidity; Gabapentin; Humans; Male; Middle Aged; Randomiz | 2022 |
Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis.
Topics: Amines; Anti-Anxiety Agents; Anxiety Disorders; Bipolar Disorder; Cyclohexanecarboxylic Acids; Doubl | 2017 |
Psychiatric concerns in pediatric epilepsy.
Topics: Adolescent; Amines; Anxiety Disorders; Bipolar Disorder; Child; Child, Preschool; Cyclohexanecarboxy | 2010 |
Understanding the pharmacokinetics of anxiolytic drugs.
Topics: Adrenergic beta-Antagonists; Amines; Anti-Anxiety Agents; Anticonvulsants; Anxiety Disorders; Atenol | 2013 |
The role of GABA in anxiety disorders.
Topics: Acetates; Amines; Anxiety Disorders; Benzodiazepines; Cyclohexanecarboxylic Acids; GABA Agents; Gaba | 2003 |
Pharmacological treatment of social anxiety disorder: a meta-analysis.
Topics: Acetates; Amines; Anti-Anxiety Agents; Antidepressive Agents; Antimanic Agents; Anxiety Disorders; C | 2003 |
2 trials available for gabapentin and Anxiety Disorders
| Article | Year |
|---|---|
Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders.
Topics: Acetates; Adult; Aged; Amines; Anti-Anxiety Agents; Anticonvulsants; Anxiety Disorders; Behavioral S | 1998 |
A beneficial effect on mood in partial epilepsy patients treated with gabapentin.
Topics: Acetates; Adult; Affect; Aged; Amines; Anticonvulsants; Anxiety Disorders; Comorbidity; Cyclohexanec | 1999 |
8 other studies available for gabapentin and Anxiety Disorders
| Article | Year |
|---|---|
Psychiatric Comorbidities and Psychiatric Medication Use Are Highly Prevalent in Patients With Eosinophilic Esophagitis and Associate With Clinical Presentation.
Topics: Adolescent; Adult; Age Distribution; Anxiety Disorders; Benzodiazepines; Chest Pain; Child; Chronic | 2020 |
Gabapentin and Pregabalin for the Treatment of Anxiety Disorders.
Topics: Anti-Anxiety Agents; Anxiety Disorders; GABA Agents; Gabapentin; Humans; Pregabalin; Treatment Outco | 2018 |
Statement of the AGNP in the Context of the Planned Formation of a Fixed Reference Price Group "GABA-Analogues", November 21, 2011.
Topics: Amines; Anti-Anxiety Agents; Anxiety Disorders; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Amino | 2012 |
Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity?
Topics: Acetates; Adult; Aged; Alcoholism; Amines; Anticonvulsants; Antimanic Agents; Anxiety Disorders; Bip | 2002 |
Anticonvulsants as anxiolytics, part 2: Pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels.
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Anxiety Disorders; Calcium Channels; Cyclohe | 2004 |
Monotherapy treatment of paruresis with gabapentin.
Topics: Amines; Anti-Anxiety Agents; Anxiety Disorders; Cyclohexanecarboxylic Acids; Dose-Response Relations | 2005 |
Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs.
Topics: Amines; Analgesics; Animals; Anti-Anxiety Agents; Anxiety Disorders; Cells, Cultured; Cyclohexanecar | 2007 |
Gabapentin as a potential treatment for anxiety disorders.
Topics: Acetates; Adult; Alprazolam; Amines; Anticonvulsants; Anxiety Disorders; Cyclohexanecarboxylic Acids | 1998 |